Irofulven second generation - Lantern Pharma

Drug Profile

Irofulven second generation - Lantern Pharma

Alternative Names: Irofulven-2; LP 184

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Lantern Pharma
  • Class Sesquiterpenes; Small molecules
  • Mechanism of Action RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ovarian cancer; Prostate cancer

Most Recent Events

  • 18 Apr 2018 Preclinical trials in Prostate cancer in USA (Parenteral)
  • 09 May 2017 LP 184 is available for licensing as of 09 May 2017.
  • 02 May 2017 Lantern Pharma plans biomarker based clinical trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top